US2022242947A1PendingUtilityA1
Provasopressin antagonists and uses thereof
Est. expiryNov 11, 2031(~5.3 yrs left)· nominal 20-yr term from priority
G01N 33/57515G01N 33/5752A61K 2039/505A61K 39/3955A61K 47/6847A61K 31/137C07K 2317/92C07K 2317/76C07K 16/3069C07K 16/303C07K 16/3023A61K 38/10C07K 2317/21C07K 16/3015C07K 2317/24C07K 16/26C07K 2317/55A61K 49/00A61K 39/39558A61K 51/1024A61P 35/00C07K 2317/77A61K 45/06G01N 33/57415G01N 33/57423
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.
Claims
exact text as granted — not AI-modified1 . A method of treating a provasopressin-expressing (pro-VP-expressing) cancer, comprising administering a therapeutically effective amount of a provasopressin-binding agent (such as an anti-provasopressin antibody or antigen-binding portion thereof) to a patient in need thereof, wherein the cancer is not small cell lung cancer (SCLC) or breast cancer.
2 - 52 . (canceled)Join the waitlist — get patent alerts
Track US2022242947A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.